The Clinic Draws Near | GenomeWeb

The Clinic Draws Near

Premium

In melanoma patients, resistance to BRAF inhibitors and the development of secondary tumors after treatment may be due to mutations in RAS, according to a study published in the January issue of the New England Journal of Medicine. In a related editorial in the same issue, the Wistar Institute's Ashani Weeraratna described BRAF inhibition as a good example of when a tailored treatment is necessary. She recommended that patients taking BRAF inhibitors be tested and their RAS status determined to reduce the risk of secondary tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.